Connect
← Return to ANA Titer 1:1280 pattern homogeneous and speckled o/w negative work-up
Discussion
ANA Titer 1:1280 pattern homogeneous and speckled o/w negative work-up
Autoimmune Diseases | Last Active: 2 days ago | Replies (42)Comment receiving replies
@windyshores - I agree 100% that ENT is not the answer but trying to get my foot in the door and trying to be open minded and agree to the referral from the rheumatologist. Heck, they are the specialists so one would think they know best. Maybe I will get an ENT like my first one who knows better and provides me with the necessary direction. Just seems like if I clinically have symptoms with an ANA that high a rheumatologist would not just come to the conclusion of glossitis unknown etiology with atypical symptoms. So frustrating. I will take Sjogren’s clinic into consideration. Likely will end up with a university rheumatologist or Mayo Clinic. I try to be hopeful but I have my days. I will continue to push myself until I am no longer in control of course. Just know the odds of a ANA being that elevated with symptoms are not in my favor. Being tossed around like this makes me feel as if these docs don’t really care about me. Book name?
Replies to "@windyshores - I agree 100% that ENT is not the answer but trying to get my..."
Connect
The Lady's Handbook for her Mysterious Illness. I didn't know your gender! It certainly applies to all but since most autoimmune illnesses afflict females, that is a focus.
In my experience rheumatologists don't got by the level of the ANA and I have read it does not correlate with clinical illness. I had an ANA of 1:5000 something and a rheumatologist claimed healthy people could have that ( Id bout it).
They have checklists of specfic symptoms and you have to check a certain number of boxes.
Is any doctor saying there is nothing wrong with you?
Since treatments are so serious in terms of potential impact, I think doctors wait until they are really sure of need. Plaquenil used to be an exception.. Of course COVID brought Plaquenil risks (hydroxychloroquine) into the limelight.